15,304 Shares in Krystal Biotech, Inc. $KRYS Purchased by EFG International AG

Posted by Francis Steltz on Aug 26th, 2026

EFG International AG acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 15,304 shares of the company’s stock, valued at approximately $5,688,000.

Several other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Krystal Biotech in the 2nd quarter valued at approximately $1,554,113,000. William Blair Investment Management LLC acquired a new position in Krystal Biotech during the 2nd quarter worth $211,909,000. Soleus Capital Management L.P. boosted its position in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the period. Norges Bank bought a new position in shares of Krystal Biotech in the fourth quarter worth $70,159,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KRYS. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. TD Cowen raised their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Finally, HC Wainwright upped their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Get Our Latest Analysis on Krystal Biotech

Insider Transactions at Krystal Biotech

In related news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock valued at $16,278,020 in the last quarter. Insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Up 4.2%

Shares of KRYS stock opened at $356.19 on Wednesday. The stock has a 50-day simple moving average of $348.02 and a 200 day simple moving average of $302.59. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The stock has a market capitalization of $10.54 billion, a P/E ratio of 44.64 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Krystal Biotech Profile

(Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.